IRB Study Number 23-749
Status Recruiting
Location Cleveland Clinic Main Campus
Institute Taussig Cancer Institute
Description
The primary objectives of the study is the proportion of patients with DLBCL with adequate diagnostic biopsies that successfully undergo DuoSeq assay for molecular subtype determination by day 1 of cycle 2 of standard-of-care therapy.
Inclusion Criteria
• Treatment naïve de novo DLBCL, aggressive B-cell lymphoma, not otherwise specified, or aggressive B-cell lymphoma including but not limited to transformed lymphoma arising from antecedent indolent lymphoma
• Age ≥18 years old
• Available tissue samples from initial diagnostic tissue biopsy
Exclusion Criteria
• Inability of patient or designated power of attorney to given consent
• No intended treatment with systemic therapy
